Generated August 2026 from current fund data.
Overview
IONQ is a quantum computing company stock trading near $44; IOYY is a newly launched options-income ETF that sells weekly put spreads on leveraged IONQ exposure, targeting a 74.76% distribution rate. The core distinction is structural: IONQ is direct equity ownership in the quantum hardware developer, while IOYY uses options strategies to manufacture income from IONQ price movements without holding the stock outright.
How they differ
IONQ is a pure play on quantum computing adoption and IonQ's competitive position in the space—you own earnings potential and long-term upside. IOYY, by contrast, sacrifices upside participation: it sells put spreads weekly to generate income, meaning it caps gains (or locks in losses) at predefined strike prices. The second key difference is volatility and return profile. IONQ carries a beta of 3.301, meaning it swings roughly three times as hard as the market in either direction; IOYY reports a beta of 0.0, reflecting its options-collar structure that decouples it from broad market moves but also constrains total return. Finally, IOYY charges a 1.07% expense ratio and distributes 74.76% annually in weekly payouts, a yield unsustainable without significant NAV erosion; IONQ pays no dividend and is held for capital appreciation or loss.
Who each is best for
IONQ: Fits investors who believe quantum computing adoption will drive long-term growth and can tolerate high volatility—the 3.301 beta suggests large percentage swings in either direction. These investors expect to realize gains from rising stock price, not income.
IOYY: Designed for investors seeking weekly cash flow from a concentrated quantum-computing bet who are willing to cap upside and accept the structural risk that a put-spread collar locks in losses during sharp declines. Fits those prioritizing current income over price appreciation and comfortable with options mechanics.
Key risks to know
* NAV erosion at extreme distribution yields. IOYY's 74.76% annualized payout vastly exceeds realistic underlying returns on an IONQ position, meaning the fund is likely distributing return of capital and eroding net asset value over time. Investors may be receiving their own capital back as "income."
* Options assignment and leverage risk. IOYY sells put spreads on leveraged IONQ ETFs, introducing embedded leverage and derivative complexity. A sharp drop in IONQ below the lower strike can force assignment, crystallizing losses that IONQ holders would merely experience as unrealized declines.
* Extreme concentration and quantum-sector timing. Both securities are single-stock exposures to IonQ, with zero portfolio diversification. IONQ's 3.301 beta amplifies this concentration; IOYY's collar dampens volatility but can't reduce the idiosyncratic risk that IonQ underperforms or quantum computing adoption stalls longer than expected.
* New fund with minimal track record. IOYY launched in November 2025 with only $5.80M in AUM. The strategy is untested through a market cycle, and weekly options rolls introduce operational and execution risk—slippage on the roll can erode returns further.
* Limited liquidity and wide spreads in IOYY. At $5.80M AUM, IOYY is thinly traded; bid-ask spreads may be wide, and exit timing could be costly. IONQ's $44 price offers deeper liquidity, though its high beta can mean large intraday moves.
Bottom line
If you want exposure to IonQ's long-term quantum-computing prospects and can stomach three-times-market volatility, IONQ provides direct ownership with no income drain. If you prioritize steady weekly distributions and will accept capped gains (and locked-in losses below strike levels), IOYY's options collar reduces daily swings—but the 74.76% yield signals aggressive NAV depletion and makes it a wasting asset rather than a true income stream. Past performance does not guarantee future results; neither fund has proven resilience through a full market downturn.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.